Associations - BCR-ABL1 F359C

BIOMARKER:

BCR-ABL1 F359C

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 F359C BCR-ABL1 F359C	Acute Lymphocytic Leukemia ALL	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials dasatinib Sensitive : B
BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	bosutinib Sensitive: C3 – Early Trials bosutinib Sensitive : C3
BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials imatinib Resistant : C3
BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	imatinib + nilotinib Resistant: D – Preclinical imatinib + nilotinib Resistant : D